Furiex Pharmaceuticals, Inc. (NASDAQ:FURX) today reported its financial and operating results for the quarter ended March 31, 2014.
Total revenues were $6.4 million for the quarter ended March 31, 2014 as compared to $39.3 million for the three months ended March 31, 2013. Royalty revenue of $6.4 million for the first quarter of 2014 related to the sale of alogliptin and related combination products in Japan and the United States, and of Priligy® in various countries outside the United States.
Help employers find you! Check out all the jobs and post your resume.
